Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Celldex Therapeutics, Inc. Celldex Therapeutics to Present at Jefferies Healthcare Conference June 04, 2024 From Celldex Therapeutics, Inc. Via GlobeNewswire Tickers CLDX Celldex Therapeutics Presents Data Demonstrating Profound Improvements in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2024 June 02, 2024 From Celldex Therapeutics, Inc. Via GlobeNewswire Tickers CLDX Celldex Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Prurigo Nodularis May 15, 2024 From Celldex Therapeutics, Inc. Via GlobeNewswire Tickers CLDX Celldex Reports First Quarter 2024 Financial Results and Provides Corporate Update May 06, 2024 From Celldex Therapeutics, Inc. Via GlobeNewswire Tickers CLDX Celldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible Urticaria April 17, 2024 From Celldex Therapeutics, Inc. Via GlobeNewswire Tickers CLDX Celldex Therapeutics to Participate in the Leerink Partners Global Biopharma Conference March 08, 2024 From Celldex Therapeutics, Inc. Via GlobeNewswire Tickers CLDX Celldex Therapeutics to Present at TD Cowen’s 44th Annual Health Care Conference March 05, 2024 From Celldex Therapeutics, Inc. Via GlobeNewswire Tickers CLDX Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares March 05, 2024 From Celldex Therapeutics, Inc. Via GlobeNewswire Tickers CLDX Celldex Therapeutics Announces Pricing of Upsized $400 Million Public Offering of Common Stock February 29, 2024 From Celldex Therapeutics, Inc. Via GlobeNewswire Tickers CLDX Celldex Therapeutics Announces Proposed Public Offering of Common Stock February 28, 2024 From Celldex Therapeutics, Inc. Via GlobeNewswire Tickers CLDX Celldex Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update February 26, 2024 From Celldex Therapeutics, Inc. Via GlobeNewswire Tickers CLDX Celldex Therapeutics Presents Positive 12 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria February 24, 2024 From Celldex Therapeutics, Inc. Via GlobeNewswire Tickers CLDX Celldex to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference February 06, 2024 From Celldex Therapeutics, Inc. Via GlobeNewswire Tickers CLDX Celldex Announces Upcoming Presentation of Barzolvolimab Phase 2 Results in Chronic Spontaneous Urticaria at AAAAI 2024 February 05, 2024 From Celldex Therapeutics, Inc. Via GlobeNewswire Tickers CLDX Celldex Therapeutics to Present at 6th Annual Evercore ISI HealthCONx Conference November 27, 2023 From Celldex Therapeutics, Inc. Via GlobeNewswire Tickers CLDX Celldex Therapeutics Announces Pricing of Public Offering of Common Stock November 07, 2023 From Celldex Therapeutics, Inc. Via GlobeNewswire Tickers CLDX Celldex Therapeutics Announces Proposed Public Offering of Common Stock November 07, 2023 From Celldex Therapeutics, Inc. Via GlobeNewswire Tickers CLDX Celldex Therapeutics Announces Positive Topline Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria November 06, 2023 From Celldex Therapeutics, Inc. Via GlobeNewswire Tickers CLDX Celldex Therapeutics Presents Positive Data from Prurigo Nodularis Phase 1b Study Demonstrating Meaningful Reduction in Itch and Skin Clearing with Single Dose 3.0 mg/kg Barzolvolimab November 05, 2023 From Celldex Therapeutics, Inc. Via GlobeNewswire Tickers CLDX Celldex Reports Third Quarter 2023 Financial Results and Provides Corporate Update November 02, 2023 From Celldex Therapeutics, Inc. Via GlobeNewswire Tickers CLDX Celldex Announces Acceptance of Abstract for Barzolvolimab Phase 1b Results in Prurigo Nodularis at 12th World Congress on Itch (WCI) 2023 September 26, 2023 From Celldex Therapeutics, Inc. Via GlobeNewswire Tickers CLDX Celldex Therapeutics to Present at Cantor Global Healthcare Conference September 25, 2023 From Celldex Therapeutics, Inc. Via GlobeNewswire Tickers CLDX Celldex Reports Second Quarter 2023 Financial Results and Provides Corporate Update August 08, 2023 From Celldex Therapeutics, Inc. Via GlobeNewswire Tickers CLDX Celldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Spontaneous Urticaria July 11, 2023 From Celldex Therapeutics, Inc. Via GlobeNewswire Tickers CLDX Celldex Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Eosinophilic Esophagitis July 06, 2023 From Celldex Therapeutics, Inc. Via GlobeNewswire Tickers CLDX Celldex Therapeutics Presents Positive Data from Barzolvolimab Chronic Urticaria Program at EAACI 2023 June 10, 2023 From Celldex Therapeutics, Inc. Via GlobeNewswire Tickers CLDX Celldex Therapeutics Announces Upcoming Barzolvolimab Presentations at EAACI 2023 June 08, 2023 From Celldex Therapeutics, Inc. Via GlobeNewswire Tickers CLDX Celldex Therapeutics to Present at Jefferies Healthcare Conference June 02, 2023 From Celldex Therapeutics, Inc. Via GlobeNewswire Tickers CLDX Celldex Announces First Patient Dosed in Phase 1 Study of CDX-585 in Patients with Advanced Malignancies May 31, 2023 From Celldex Therapeutics, Inc. Via GlobeNewswire Tickers CLDX Celldex Therapeutics Presents Positive Preclinical Data from TSLP/SCF Bispecific Antibody Program CDX-622 at IMMUNOLOGY2023™ May 15, 2023 From Celldex Therapeutics, Inc. Via GlobeNewswire Tickers CLDX Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.